Gertrud E. Feiersinger

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells

M. Hermann, J. Bouchal, Z. Culig, 2018, Molecular oncology.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, Oncotarget.

Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015 .

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, OncoTarget.